139 related articles for article (PubMed ID: 8555577)
1. Reversal of anticoagulation without protamine using a heparin removal device after cardiopulmonary bypass.
Vertress RA; Zwischenberger JB; McRea JC; Tao W; Kurusz M; Conti VR
ASAIO J; 1994; 40(3):M560-4. PubMed ID: 8555577
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device--an alternative to protamine.
Tao W; Deyo DJ; Brunston RL; Vertrees RA; Zwischenberger JB
Crit Care Med; 1998 Jun; 26(6):1096-102. PubMed ID: 9635661
[TBL] [Abstract][Full Text] [Related]
4. The use of a heparin removal device: a valid alternative to protamine.
Hendrikx M; Leunens V; Vandezande E; Wallyn A; Flameng W
Int J Artif Organs; 1997 Mar; 20(3):166-74. PubMed ID: 9151153
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a heparin removal device: a prospective randomized preclinical outcomes study.
Zwischenberger JB; Tao W; Deyo DJ; Vertrees RA; Alpard SK; Shulman G
Ann Thorac Surg; 2001 Jan; 71(1):270-7. PubMed ID: 11216760
[TBL] [Abstract][Full Text] [Related]
6. Heparin clearance profiles after systemic anticoagulation using a heparin removal device system.
Tao W; Callahan JD; Vertrees RA; Brunston RL; Deyo DJ; McRea JC; Zwischenberger JB
ASAIO J; 1997; 43(6):922-6. PubMed ID: 9386844
[TBL] [Abstract][Full Text] [Related]
7. Flow rate dependent ex vivo deheparinization with immobilized cationic ligand.
Tevaearai HT; Mueller XM; Marty B; Horisberger J; Schapira M; von Segesser LK
ASAIO J; 1997; 43(5):M487-9. PubMed ID: 9360090
[TBL] [Abstract][Full Text] [Related]
8. Significant reduction in circuit pressure with modified plasma separation chamber for a heparin removal device.
Tao W; Deyo DJ; Alpard SK; Vertrees RA; Hoang V; Zwischenberger JB
ASAIO J; 1999; 45(1):50-2. PubMed ID: 9952007
[TBL] [Abstract][Full Text] [Related]
9. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
[TBL] [Abstract][Full Text] [Related]
10. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
[TBL] [Abstract][Full Text] [Related]
11. Assembly of the Heparin Removal Device for patients with suspected adverse reaction to protamine sulphate.
Jegger D; Tevaerai HT; Horisberger J; Mueller XM; Seigneuil I; Pierrel N; Boone Y; von Segesser LK
Perfusion; 2000 Sep; 15(5):453-6. PubMed ID: 11001169
[TBL] [Abstract][Full Text] [Related]
12. Heparin removal after cardiopulmonary bypass in a patient with adverse reaction to protamine.
Tevaearai HT; Jegger D; Mueller XM; Horisberger J; von Segesser LK
Thorac Cardiovasc Surg; 1998 Oct; 46(5):303-4. PubMed ID: 9885123
[TBL] [Abstract][Full Text] [Related]
13. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
[TBL] [Abstract][Full Text] [Related]
14. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects.
Ovrum E; Holen EA; Tangen G; Brosstad F; Abdelnoor M; Ringdal MA; Oystese R; Istad R
Ann Thorac Surg; 1995 Aug; 60(2):365-71. PubMed ID: 7646097
[TBL] [Abstract][Full Text] [Related]
15. Real time measurement of heparin concentration during cardiopulmonary bypass.
Hashimoto K; Sasaki T; Hachiya T; Takakura H; Onoguchi K; Nagahori R; Takeuchi S
J Cardiovasc Surg (Torino); 1999 Oct; 40(5):645-51. PubMed ID: 10596996
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
[TBL] [Abstract][Full Text] [Related]
17. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
[TBL] [Abstract][Full Text] [Related]
18. Automated protamine dose assay in heparin reversal management after cardiopulmonary by pass.
Guarracino F; De Cosmo D; Penzo D; Tedesco M; Bossi A; Zussa C; Polesel E; De Stefani R
Minerva Anestesiol; 2001 Apr; 67(4):165-9. PubMed ID: 11376504
[TBL] [Abstract][Full Text] [Related]
19. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
[TBL] [Abstract][Full Text] [Related]
20. Reduction and elimination of systemic heparinization during cardiopulmonary bypass.
von Segesser LK; Weiss BM; Garcia E; von Felten A; Turina MI
J Thorac Cardiovasc Surg; 1992 Apr; 103(4):790-8; discussion 798-9. PubMed ID: 1548923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
